Catalyst Pharmaceuticals Inc. announced that its Board of Directors has authorized a share repurchase program of up to $200 million of its outstanding common stock. The buyback program will be funded using existing cash on hand and is set to run between October 1, 2025, and December 31, 2026. The timing and amount of purchases will depend on various factors, including stock price and market conditions. Catalyst is not obligated to repurchase any specific amount of shares, and the program may be suspended or terminated at any time. The company had more than $650 million in cash and cash equivalents as of June 30, 2025, and no funded debt.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538350-en) on October 01, 2025, and is solely responsible for the information contained therein.